Protocol

Hou et al. 2024 independent validation, Zhou et al. liver cancer cohort (Table S3)

Fragmentation pattern comparison by Hou et al. 2024.

Overview

Fragmentation pattern comparison by Hou et al. 2024.

Consult the linked sources for architecture or protocol details. Missing evidence is not evidence of a missing capability.

10 recorded evaluations, 30 metric rows. A comparison chart has not yet been validated for these results. The table retains the individual findings and their sources.

View coverage and remaining gaps across all benchmarks

Results

Results are available, but no reviewed comparison panel is linked in this release.

All evaluations

10 evaluations · 30 results. Different protocols are not a single leaderboard.

Filter evaluations

Tested model or methodProtocolDatasetEvaluation setupMetricEvidence origin

Applied filters: All linked evaluations

Exact evaluated configurations and original reported results
Tested configuration	Protocol and dataset	Finding	Evidence and details
Configuration: Fragment 5' end motif (4-mer), open chromatin regions, SVM (Hou et al. 2024)	Protocol: Hou et al. 2024 independent validation, Zhou et al. liver cancer cohort (Table S3) Dataset: Zhou et al. 2022 plasma WGS, 8 liver cancer and 8 healthy (as used by Hou et al. 2024)	0.891 auroc unitless · higher Uncertainty: Not reported by the source Coverage: Not reported scored / Not reported eligible	Independent external evaluation · Source checked Methods, coverage and source EDM (open chromatin), independent validation on Zhou et al. dataset (LIHC) ctdnafrag-20261009-protocol-hou2024-zhou-lihc-independent Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S3, C12; data set 'Zhou et al. dataset (LIHC)'; row 'EDM'; column 'AUC'
Configuration: Fragment 5' end motif (4-mer), open chromatin regions, SVM (Hou et al. 2024)	Protocol: Hou et al. 2024 independent validation, Zhou et al. liver cancer cohort (Table S3) Dataset: Zhou et al. 2022 plasma WGS, 8 liver cancer and 8 healthy (as used by Hou et al. 2024)	0.75 sensitivity-at-85-percent-specificity fraction · higher Uncertainty: Not reported by the source Coverage: Not reported scored / Not reported eligible	Independent external evaluation · Source checked Methods, coverage and source EDM (open chromatin), independent validation on Zhou et al. dataset (LIHC) ctdnafrag-20261009-protocol-hou2024-zhou-lihc-independent Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S3, E12; data set 'Zhou et al. dataset (LIHC)'; row 'EDM'; column 'Sensitivity @85% specificity'
Configuration: Fragment 5' end motif (4-mer), open chromatin regions, SVM (Hou et al. 2024)	Protocol: Hou et al. 2024 independent validation, Zhou et al. liver cancer cohort (Table S3) Dataset: Zhou et al. 2022 plasma WGS, 8 liver cancer and 8 healthy (as used by Hou et al. 2024)	0.75 sensitivity-at-95-percent-specificity fraction · higher Uncertainty: Not reported by the source Coverage: Not reported scored / Not reported eligible	Independent external evaluation · Source checked Methods, coverage and source EDM (open chromatin), independent validation on Zhou et al. dataset (LIHC) ctdnafrag-20261009-protocol-hou2024-zhou-lihc-independent Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S3, D12; data set 'Zhou et al. dataset (LIHC)'; row 'EDM'; column 'Sensitivity @95% specificity'
Configuration: Fragment coverage (fragment midpoint counts), open chromatin regions, SVM (Hou et al. 2024)	Protocol: Hou et al. 2024 independent validation, Zhou et al. liver cancer cohort (Table S3) Dataset: Zhou et al. 2022 plasma WGS, 8 liver cancer and 8 healthy (as used by Hou et al. 2024)	0.797 auroc unitless · higher Uncertainty: Not reported by the source Coverage: Not reported scored / Not reported eligible	Independent external evaluation · Source checked Methods, coverage and source coverage (open chromatin), independent validation on Zhou et al. dataset (LIHC) ctdnafrag-20261009-protocol-hou2024-zhou-lihc-independent Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S3, C7; data set 'Zhou et al. dataset (LIHC)'; row 'coverage'; column 'AUC'
Configuration: Fragment coverage (fragment midpoint counts), open chromatin regions, SVM (Hou et al. 2024)	Protocol: Hou et al. 2024 independent validation, Zhou et al. liver cancer cohort (Table S3) Dataset: Zhou et al. 2022 plasma WGS, 8 liver cancer and 8 healthy (as used by Hou et al. 2024)	0.625 sensitivity-at-85-percent-specificity fraction · higher Uncertainty: Not reported by the source Coverage: Not reported scored / Not reported eligible	Independent external evaluation · Source checked Methods, coverage and source coverage (open chromatin), independent validation on Zhou et al. dataset (LIHC) ctdnafrag-20261009-protocol-hou2024-zhou-lihc-independent Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S3, E7; data set 'Zhou et al. dataset (LIHC)'; row 'coverage'; column 'Sensitivity @85% specificity'
Configuration: Fragment coverage (fragment midpoint counts), open chromatin regions, SVM (Hou et al. 2024)	Protocol: Hou et al. 2024 independent validation, Zhou et al. liver cancer cohort (Table S3) Dataset: Zhou et al. 2022 plasma WGS, 8 liver cancer and 8 healthy (as used by Hou et al. 2024)	0.125 sensitivity-at-95-percent-specificity fraction · higher Uncertainty: Not reported by the source Coverage: Not reported scored / Not reported eligible	Independent external evaluation · Source checked Methods, coverage and source coverage (open chromatin), independent validation on Zhou et al. dataset (LIHC) ctdnafrag-20261009-protocol-hou2024-zhou-lihc-independent Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S3, D7; data set 'Zhou et al. dataset (LIHC)'; row 'coverage'; column 'Sensitivity @95% specificity'
Configuration: Fragment endpoint counts, open chromatin regions, SVM (Hou et al. 2024)	Protocol: Hou et al. 2024 independent validation, Zhou et al. liver cancer cohort (Table S3) Dataset: Zhou et al. 2022 plasma WGS, 8 liver cancer and 8 healthy (as used by Hou et al. 2024)	0.922 auroc unitless · higher Uncertainty: Not reported by the source Coverage: Not reported scored / Not reported eligible	Independent external evaluation · Source checked Methods, coverage and source end (open chromatin), independent validation on Zhou et al. dataset (LIHC) ctdnafrag-20261009-protocol-hou2024-zhou-lihc-independent Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S3, C8; data set 'Zhou et al. dataset (LIHC)'; row 'end'; column 'AUC'
Configuration: Fragment endpoint counts, open chromatin regions, SVM (Hou et al. 2024)	Protocol: Hou et al. 2024 independent validation, Zhou et al. liver cancer cohort (Table S3) Dataset: Zhou et al. 2022 plasma WGS, 8 liver cancer and 8 healthy (as used by Hou et al. 2024)	0.875 sensitivity-at-85-percent-specificity fraction · higher Uncertainty: Not reported by the source Coverage: Not reported scored / Not reported eligible	Independent external evaluation · Source checked Methods, coverage and source end (open chromatin), independent validation on Zhou et al. dataset (LIHC) ctdnafrag-20261009-protocol-hou2024-zhou-lihc-independent Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S3, E8; data set 'Zhou et al. dataset (LIHC)'; row 'end'; column 'Sensitivity @85% specificity'
Configuration: Fragment endpoint counts, open chromatin regions, SVM (Hou et al. 2024)	Protocol: Hou et al. 2024 independent validation, Zhou et al. liver cancer cohort (Table S3) Dataset: Zhou et al. 2022 plasma WGS, 8 liver cancer and 8 healthy (as used by Hou et al. 2024)	0.5 sensitivity-at-95-percent-specificity fraction · higher Uncertainty: Not reported by the source Coverage: Not reported scored / Not reported eligible	Independent external evaluation · Source checked Methods, coverage and source end (open chromatin), independent validation on Zhou et al. dataset (LIHC) ctdnafrag-20261009-protocol-hou2024-zhou-lihc-independent Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S3, D8; data set 'Zhou et al. dataset (LIHC)'; row 'end'; column 'Sensitivity @95% specificity'
Configuration: Fragment length distribution, open chromatin regions, SVM (Hou et al. 2024)	Protocol: Hou et al. 2024 independent validation, Zhou et al. liver cancer cohort (Table S3) Dataset: Zhou et al. 2022 plasma WGS, 8 liver cancer and 8 healthy (as used by Hou et al. 2024)	0.5 auroc unitless · higher Uncertainty: Not reported by the source Coverage: Not reported scored / Not reported eligible	Independent external evaluation · Source checked Methods, coverage and source length (open chromatin), independent validation on Zhou et al. dataset (LIHC) ctdnafrag-20261009-protocol-hou2024-zhou-lihc-independent Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S3, C3; data set 'Zhou et al. dataset (LIHC)'; row 'length'; column 'AUC'
Configuration: Fragment length distribution, open chromatin regions, SVM (Hou et al. 2024)	Protocol: Hou et al. 2024 independent validation, Zhou et al. liver cancer cohort (Table S3) Dataset: Zhou et al. 2022 plasma WGS, 8 liver cancer and 8 healthy (as used by Hou et al. 2024)	0.25 sensitivity-at-85-percent-specificity fraction · higher Uncertainty: Not reported by the source Coverage: Not reported scored / Not reported eligible	Independent external evaluation · Source checked Methods, coverage and source length (open chromatin), independent validation on Zhou et al. dataset (LIHC) ctdnafrag-20261009-protocol-hou2024-zhou-lihc-independent Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S3, E3; data set 'Zhou et al. dataset (LIHC)'; row 'length'; column 'Sensitivity @85% specificity'
Configuration: Fragment length distribution, open chromatin regions, SVM (Hou et al. 2024)	Protocol: Hou et al. 2024 independent validation, Zhou et al. liver cancer cohort (Table S3) Dataset: Zhou et al. 2022 plasma WGS, 8 liver cancer and 8 healthy (as used by Hou et al. 2024)	0 sensitivity-at-95-percent-specificity fraction · higher Uncertainty: Not reported by the source Coverage: Not reported scored / Not reported eligible	Independent external evaluation · Source checked Methods, coverage and source length (open chromatin), independent validation on Zhou et al. dataset (LIHC) ctdnafrag-20261009-protocol-hou2024-zhou-lihc-independent Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S3, D3; data set 'Zhou et al. dataset (LIHC)'; row 'length'; column 'Sensitivity @95% specificity'
Configuration: Fragment size distribution (FSD), open chromatin regions, SVM (Hou et al. 2024)	Protocol: Hou et al. 2024 independent validation, Zhou et al. liver cancer cohort (Table S3) Dataset: Zhou et al. 2022 plasma WGS, 8 liver cancer and 8 healthy (as used by Hou et al. 2024)	0.563 auroc unitless · higher Uncertainty: Not reported by the source Coverage: Not reported scored / Not reported eligible	Independent external evaluation · Source checked Methods, coverage and source FSD (open chromatin), independent validation on Zhou et al. dataset (LIHC) ctdnafrag-20261009-protocol-hou2024-zhou-lihc-independent Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S3, C6; data set 'Zhou et al. dataset (LIHC)'; row 'FSD'; column 'AUC'
Configuration: Fragment size distribution (FSD), open chromatin regions, SVM (Hou et al. 2024)	Protocol: Hou et al. 2024 independent validation, Zhou et al. liver cancer cohort (Table S3) Dataset: Zhou et al. 2022 plasma WGS, 8 liver cancer and 8 healthy (as used by Hou et al. 2024)	0.5 sensitivity-at-85-percent-specificity fraction · higher Uncertainty: Not reported by the source Coverage: Not reported scored / Not reported eligible	Independent external evaluation · Source checked Methods, coverage and source FSD (open chromatin), independent validation on Zhou et al. dataset (LIHC) ctdnafrag-20261009-protocol-hou2024-zhou-lihc-independent Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S3, E6; data set 'Zhou et al. dataset (LIHC)'; row 'FSD'; column 'Sensitivity @85% specificity'
Configuration: Fragment size distribution (FSD), open chromatin regions, SVM (Hou et al. 2024)	Protocol: Hou et al. 2024 independent validation, Zhou et al. liver cancer cohort (Table S3) Dataset: Zhou et al. 2022 plasma WGS, 8 liver cancer and 8 healthy (as used by Hou et al. 2024)	0.125 sensitivity-at-95-percent-specificity fraction · higher Uncertainty: Not reported by the source Coverage: Not reported scored / Not reported eligible	Independent external evaluation · Source checked Methods, coverage and source FSD (open chromatin), independent validation on Zhou et al. dataset (LIHC) ctdnafrag-20261009-protocol-hou2024-zhou-lihc-independent Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S3, D6; data set 'Zhou et al. dataset (LIHC)'; row 'FSD'; column 'Sensitivity @95% specificity'
Configuration: Fragment size ratio (FSR), open chromatin regions, SVM (Hou et al. 2024)	Protocol: Hou et al. 2024 independent validation, Zhou et al. liver cancer cohort (Table S3) Dataset: Zhou et al. 2022 plasma WGS, 8 liver cancer and 8 healthy (as used by Hou et al. 2024)	0.813 auroc unitless · higher Uncertainty: Not reported by the source Coverage: Not reported scored / Not reported eligible	Independent external evaluation · Source checked Methods, coverage and source FSR (open chromatin), independent validation on Zhou et al. dataset (LIHC) ctdnafrag-20261009-protocol-hou2024-zhou-lihc-independent Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S3, C5; data set 'Zhou et al. dataset (LIHC)'; row 'FSR'; column 'AUC'
Configuration: Fragment size ratio (FSR), open chromatin regions, SVM (Hou et al. 2024)	Protocol: Hou et al. 2024 independent validation, Zhou et al. liver cancer cohort (Table S3) Dataset: Zhou et al. 2022 plasma WGS, 8 liver cancer and 8 healthy (as used by Hou et al. 2024)	0.5 sensitivity-at-85-percent-specificity fraction · higher Uncertainty: Not reported by the source Coverage: Not reported scored / Not reported eligible	Independent external evaluation · Source checked Methods, coverage and source FSR (open chromatin), independent validation on Zhou et al. dataset (LIHC) ctdnafrag-20261009-protocol-hou2024-zhou-lihc-independent Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S3, E5; data set 'Zhou et al. dataset (LIHC)'; row 'FSR'; column 'Sensitivity @85% specificity'
Configuration: Fragment size ratio (FSR), open chromatin regions, SVM (Hou et al. 2024)	Protocol: Hou et al. 2024 independent validation, Zhou et al. liver cancer cohort (Table S3) Dataset: Zhou et al. 2022 plasma WGS, 8 liver cancer and 8 healthy (as used by Hou et al. 2024)	0.375 sensitivity-at-95-percent-specificity fraction · higher Uncertainty: Not reported by the source Coverage: Not reported scored / Not reported eligible	Independent external evaluation · Source checked Methods, coverage and source FSR (open chromatin), independent validation on Zhou et al. dataset (LIHC) ctdnafrag-20261009-protocol-hou2024-zhou-lihc-independent Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S3, D5; data set 'Zhou et al. dataset (LIHC)'; row 'FSR'; column 'Sensitivity @95% specificity'
Configuration: Integrated fragmentation score (IFS), open chromatin regions, SVM (Hou et al. 2024)	Protocol: Hou et al. 2024 independent validation, Zhou et al. liver cancer cohort (Table S3) Dataset: Zhou et al. 2022 plasma WGS, 8 liver cancer and 8 healthy (as used by Hou et al. 2024)	0.813 auroc unitless · higher Uncertainty: Not reported by the source Coverage: Not reported scored / Not reported eligible	Author-reported evaluation · Source checked Methods, coverage and source IFS (open chromatin), independent validation on Zhou et al. dataset (LIHC) ctdnafrag-20261009-protocol-hou2024-zhou-lihc-independent Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S3, C10; data set 'Zhou et al. dataset (LIHC)'; row 'IFS'; column 'AUC'
Configuration: Integrated fragmentation score (IFS), open chromatin regions, SVM (Hou et al. 2024)	Protocol: Hou et al. 2024 independent validation, Zhou et al. liver cancer cohort (Table S3) Dataset: Zhou et al. 2022 plasma WGS, 8 liver cancer and 8 healthy (as used by Hou et al. 2024)	0.625 sensitivity-at-85-percent-specificity fraction · higher Uncertainty: Not reported by the source Coverage: Not reported scored / Not reported eligible	Author-reported evaluation · Source checked Methods, coverage and source IFS (open chromatin), independent validation on Zhou et al. dataset (LIHC) ctdnafrag-20261009-protocol-hou2024-zhou-lihc-independent Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S3, E10; data set 'Zhou et al. dataset (LIHC)'; row 'IFS'; column 'Sensitivity @85% specificity'
Configuration: Integrated fragmentation score (IFS), open chromatin regions, SVM (Hou et al. 2024)	Protocol: Hou et al. 2024 independent validation, Zhou et al. liver cancer cohort (Table S3) Dataset: Zhou et al. 2022 plasma WGS, 8 liver cancer and 8 healthy (as used by Hou et al. 2024)	0.125 sensitivity-at-95-percent-specificity fraction · higher Uncertainty: Not reported by the source Coverage: Not reported scored / Not reported eligible	Author-reported evaluation · Source checked Methods, coverage and source IFS (open chromatin), independent validation on Zhou et al. dataset (LIHC) ctdnafrag-20261009-protocol-hou2024-zhou-lihc-independent Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S3, D10; data set 'Zhou et al. dataset (LIHC)'; row 'IFS'; column 'Sensitivity @95% specificity'
Configuration: Orientation-aware cell-free fragmentation (OCF), open chromatin regions, SVM (Hou et al. 2024)	Protocol: Hou et al. 2024 independent validation, Zhou et al. liver cancer cohort (Table S3) Dataset: Zhou et al. 2022 plasma WGS, 8 liver cancer and 8 healthy (as used by Hou et al. 2024)	0.875 auroc unitless · higher Uncertainty: Not reported by the source Coverage: Not reported scored / Not reported eligible	Independent external evaluation · Source checked Methods, coverage and source OCF (open chromatin), independent validation on Zhou et al. dataset (LIHC) ctdnafrag-20261009-protocol-hou2024-zhou-lihc-independent Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S3, C9; data set 'Zhou et al. dataset (LIHC)'; row 'OCF'; column 'AUC'
Configuration: Orientation-aware cell-free fragmentation (OCF), open chromatin regions, SVM (Hou et al. 2024)	Protocol: Hou et al. 2024 independent validation, Zhou et al. liver cancer cohort (Table S3) Dataset: Zhou et al. 2022 plasma WGS, 8 liver cancer and 8 healthy (as used by Hou et al. 2024)	0.625 sensitivity-at-85-percent-specificity fraction · higher Uncertainty: Not reported by the source Coverage: Not reported scored / Not reported eligible	Independent external evaluation · Source checked Methods, coverage and source OCF (open chromatin), independent validation on Zhou et al. dataset (LIHC) ctdnafrag-20261009-protocol-hou2024-zhou-lihc-independent Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S3, E9; data set 'Zhou et al. dataset (LIHC)'; row 'OCF'; column 'Sensitivity @85% specificity'
Configuration: Orientation-aware cell-free fragmentation (OCF), open chromatin regions, SVM (Hou et al. 2024)	Protocol: Hou et al. 2024 independent validation, Zhou et al. liver cancer cohort (Table S3) Dataset: Zhou et al. 2022 plasma WGS, 8 liver cancer and 8 healthy (as used by Hou et al. 2024)	0.625 sensitivity-at-95-percent-specificity fraction · higher Uncertainty: Not reported by the source Coverage: Not reported scored / Not reported eligible	Independent external evaluation · Source checked Methods, coverage and source OCF (open chromatin), independent validation on Zhou et al. dataset (LIHC) ctdnafrag-20261009-protocol-hou2024-zhou-lihc-independent Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S3, D9; data set 'Zhou et al. dataset (LIHC)'; row 'OCF'; column 'Sensitivity @95% specificity'
Configuration: Promoter fragmentation entropy (PFE), open chromatin regions, SVM (Hou et al. 2024)	Protocol: Hou et al. 2024 independent validation, Zhou et al. liver cancer cohort (Table S3) Dataset: Zhou et al. 2022 plasma WGS, 8 liver cancer and 8 healthy (as used by Hou et al. 2024)	0.766 auroc unitless · higher Uncertainty: Not reported by the source Coverage: Not reported scored / Not reported eligible	Independent external evaluation · Source checked Methods, coverage and source PFE (open chromatin), independent validation on Zhou et al. dataset (LIHC) ctdnafrag-20261009-protocol-hou2024-zhou-lihc-independent Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S3, C4; data set 'Zhou et al. dataset (LIHC)'; row 'PFE'; column 'AUC'

Source checking is not independent reproduction. Release 2026-10-09-ba02f2f4a36e.

Methods and evaluation design

Procedure, tasks and evaluated configurations

Recorded evaluations

Each evaluation records what was tested and under which conditions.

Baseline coverage

Reference methods help show what a model adds beyond simple controls. We track a null control and a conventional method for each protocol.

0 of 2 active baseline roles have published Rewire measurements in this release. Measurements on a selected protocol do not establish coverage of an entire suite.

No execution recipe linked to this protocol. Recipe availability does not establish a completed evaluation.

Author-reported evaluations: 1
External evaluations: 9

Literature evidence is not a Rewire measurement. Executed but unpublished runs and private review status are not included.

Null control

Proposed control: requires review

Select a task-valid null control after reviewing inputs and metric

Protocol-specific applicability, permitted inputs, access, split, evaluator and execution requirements need review before implementation or execution.

This is a suggested selection rule, not a validated method or a measured score.

Conventional reference

Proposed control: requires review

Select an upstream conventional reference after reviewing the full protocol

Protocol-specific applicability, permitted inputs, access, split, evaluator and execution requirements need review before implementation or execution.

This is a suggested selection rule, not a validated method or a measured score.

Protocol coverage CSV (gzip) · Model evaluation matrix (gzip) · Source table (gzip) · Release and checksums (gzip)

Coverage is derived from release 2026-10-09-ba02f2f4a36e. Source citations describe the original records; they do not validate an unreviewed baseline proposal. No results have been generated by this audit.

Run instructions

No runnable recipe has been reviewed for this protocol. Dataset access, model requirements, licences and compute requirements must be checked against its sources before execution.

Strengths, limitations and unresolved questions

Evidence

Source checking verifies the cited claim or transcription. It does not establish independent reproduction.

Evidence table

Inspect claims, sources and review details

Trace each statement to its source and review. A context-only reference supports the record generally; it does not verify an individual field. Source checking does not reproduce an experiment.

One row per statement and cited source. Multiple citations are not independent evaluations. Shared locators are labelled explicitly.

0 evidence rows matching the loaded filters

Claims, original sources and review scope · Release 2026-10-09-ba02f2f4a36e
Property and statement	Original source and location	Review and provenance

No evidence rows match these filters. Choose another scope or clear the search.

All evidence (JSONL) (gzip)How to read the evidence

Sources and history

Release 2026-10-09-ba02f2f4a36e · Record review: source checked

2 source records and release history

Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns · Original source · Advanced Science 11(30):e2308243, published 2024-06-17; PMC11321639 full-text XML
Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Original source · ADVS-11-2308243-s001.xlsx, PMC open-access copy PMC11321639.1

Download this release (gzip)

Technical metadata and extraction receipts

Stable ID: ctdnafrag-20261009-protocol-hou2024-zhou-lihc-independent

areas: dna-genomes
contexts: clinical_research
protocol: SVM trained on all Jiang et al. samples, applied to the Zhou et al. cohort. Report ROC-AUC and sensitivity at 95% and at 85% specificity.
version: Hou et al. 2024 Supporting Information; Methods P41, P44, P45
metric: auroc
metric direction: higher
limitations: Table S3 sensitivities have no second table to check them against; two blocks of Table S2 in the same file are disputed.; Ten fragmentation patterns restricted to open chromatin regions, one SVM each; no tumour-fraction stratification.; Eight cancers and eight controls; each sensitivity step is 0.125.; The cohort was published by Hou et al.'s corresponding author (Zhou et al. 2022, ref 10).; IFS was defined by Hou et al.'s corresponding author (Zhou et al. 2022, ref 10), so its evaluations are author-reported; the other nine patterns are independent re-implementations.
source locator: Supporting Information Table S3 rows 3-12; Experimental Section P41, P44, P45

Related records

Suggest a correction